Universal CAR T cells produce rapid remissions and enable allogeneic stem cell transplants in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.

A rigorous medical journey ends in a breakthrough, in the form of CAR-T therapy, achieving a rare, hard-won cancer-free result.

An expert discusses IL-18-armored CAR T cells for adults with relapsed B-cell leukemia, showing complete remissions with ...

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

Miguel-Angel Perales, MD, spoke with Targeted Oncology® about the problems the CAR T Vision group has identified and the key short-term and long-term steps being taken to expand the accessibility of ...

For starters, she pointed out that standard CAR-T therapy involves a lymphodepletion regimen with cyclophosphamide and ...

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor ...

Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to ...

In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy blood-forming cells. If the disease recurs after treatment or fails to respond, CAR ...

Research presented December 8 at the American Society of Hematology Conference in Florida, has shown that a new kind of CAR T-cell therapy, which generates CAR T-cells inside the body, could offer a ...

Scientists present a new approach that could empower the immune system to combat cancer cells and pave the way for new ...